Previous 10 | Next 10 |
Gainers: ReWalk Robotics (RWLK) +18%, Aldeyra Therapeutics (ALDX) +19%, ClearPoint Neuro (CLPT) +15%, ProPhase Labs (PRPH) +12%, Orchard Therapeutics (ORTX) +11%.Losers: Biomerica (BMRA) -20%, Adaptimmune Therapeutics (ADAP) -14%, Ca...
Adaptimmune Therapeutics (ADAP) has announced early release of the abstract from SURPASS Phase 1 trial with ADPA2M4CD8, a SPEAR T-cell therapy by the Society for the Immunotherapy of Cancer ((SITC)) Conference.Ongoing trial is evaluating safety and efficacy of ADP-A2M4CD8. Prior to ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and pr...
Spend each day trying to be a little wiser than you were when you woke up. Day by day, and at the end of the day if you live long enough like most people, you will get out of life what you deserve. - Charlie Munger (Warren Buffett's partner) In cancer research, CAR T-cell therapy has bee...
In a year dominated by the Covid crisis and the search for a treatment/vaccine, the last week has seen progress in the fight against cancer, and helped send the biotech sector surging. More news on: Gilead Sciences, Inc., Merck & Co., Inc., Immunomedics, Inc., , News on ETFs Read mo...
The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this Read more ...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented data from its Phase 1 trial with SPEAR T-cells targeting AFP at the virtual Inte...
Data from Enanta Pharmaceuticals' (NASDAQ: ENTA ) development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be virtually presented at the European Association for the Study of the Liver Annual Meeting. More news on: Enanta Pharmaceuticals, Inc....
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Volatility watch: Heading into the new week, short interest is on the rise on Royal Bank of Canada (NYSE: RY ) ahead of the bank's earnings report on August 26 and AstraZeneca (NYSE: AZN ) amid COVID-19 developments. Meanwhile, GameStop (NYSE: GME ) is cruising along with an exceedi...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...